期刊
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 9, 期 4, 页码 405-413出版社
EXPERT REVIEWS
DOI: 10.1586/ERI.10.178
关键词
biologic therapy; biomarkers; cellular immunity; humoral immunity; immune monitoring; immunosuppressive therapy; infection; risk factors
资金
- Fondo de Investigacion Sanitaria, Madrid, Spain [FIS 05/0839, FIS 081430]
- Grifols International, Barcelona, Spain
- European Molecular Biology Organization
- Fundacion para la Investigacion Biomedica del Hospital Gregorio Maranon, Madrid, Spain
Immunosuppressive and biologic therapies are costly and can involve a considerable risk of infection. Noninvasive diagnostic tools for early prediction of infection before and after administration of these therapies are of major interest. Serial longitudinal immune monitoring would provide data on immunocompetence and complement clinical follow-up protocols. Biomarkers of immune response may be useful to identify patients at risk of developing infection and who could be candidates for immunosuppressant dose reduction. This article focuses on the potential use of biomarkers of immune response to predict development of infection after immunosuppressive and biologic therapies in selected settings of autoimmune disease (rituximab for treatment of rheumatoid arthritis) and solid organ transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据